The introduction of the fecal immunochemical test (FIT) for colorectal cancer (CRC) screening has brought significant advantages over the previous guaiac fecal occult blood test (gFOBT), particularly regarding the need for dietary restrictions [1–3]. More crucially, FIT has transformed the qualitative assessment of gFOBT, limited to positive or negative results, into a quantitative evaluation of CRC risk [4]. Approximately 5 % (ranging from 3 % to 6 %) of FIT would be found positive [4], with positive FIT commonly defined as ≧20 μg Hb/g of feces.
